Anthony D. Baughn

The paper identifies acylaminooxadiazole derivatives that kill mycobacteria by inhibiting trans-translation and disrupting iron homeostasis.

This study shows that MHC II and CD4 T cell help are essential for pyrazinamide's antitubercular efficacy, revealing a host-mediated mechanism for its in vivo activity.

The paper develops an orally effective biotin inhibitor, C48, against Mycobacterium tuberculosis, demonstrating in vivo efficacy in a low-biotin mouse model.

This study identifies a dual mechanism of action for morphazinamide, a more potent pyrazinamide analog, showing it kills Mycobacterium tuberculosis through coenzyme A disruption and aldehyde release, which also bypasses resistance.

The paper shows that MBX-4132, a trans-translation inhibitor, kills Mycobacterium tuberculosis and non-tuberculous mycobacteria, with zinc enhancing its activity and iron reducing it.

This study shows that pyrazinamide's bactericidal activity against Mycobacterium tuberculosis is enhanced by host-derived reactive oxygen species and thiol oxidation, highlighting the role of oxidative stress in PZA efficacy.

The paper uses CRISPRi to predict synergistic antibiotic targets in E. coli by testing gene co-repression and identifying novel interactions.

The paper identifies strain-specific genetic requirements for hypoxic growth in Mycobacterium intracellulare using transposon sequencing and validates findings in a mouse infection model.

This study identifies novel anti-TB pro-drugs based on α-aminooxyacetic acid that are effective against M. tuberculosis and show low cytotoxicity.

The paper updates functional annotations for Mycobacterium tuberculosis genes using literature curation and structural modeling, identifying resistance, metabolic, and virulence genes.

This study identifies conditionally essential metabolic pathways in Mycobacterium tuberculosis using Tn-seq and in silico models, revealing gaps in current knowledge of its metabolic capabilities.